Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 16, 2003 - Issue 1
Submit an article Journal homepage
189
Views
11
CrossRef citations to date
0
Altmetric
Articles

History of the Baylor Charles A. Sammons Cancer Center

Marvin J. Stone
, MD,
Billie E. Aronoff
, MD,
W. Phil Evans
, MD,
Joseph W. Fay
, MD,
Z. H. Lieberman
, MD,
Carolyn M. Matthews
, MD,
George J. Race
, MD, PhD,
R. Pickett Scruggs
, MD &
C. Allen Stringer Jr.
, MD show all
Pages 30-58 | Published online: 11 Dec 2017

  • American Cancer Society. Cancer Facts and Figures 2002. Available at http://www.cancer.org/downloads/STT/CancerFacts&Figures2002TM.pdf.
  • Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94: 2766–2792.
  • Osler W. Chauvinism in medicine. In Aequanimitas and Other Addresses to Medical Students, Nurses and Practitioners of Medicine, 3rd ed. New York: Blakiston, 1932: 265–289.
  • Greaves M. Cancer: The Evolutionary Legacy. Oxford: Oxford University Press, 2000.
  • Huxley J. Biological Aspects of Cancer. London: Allen and Unwin, 1958.
  • Oberling C. The Riddle of Cancer, rev ed. Woglom WH, trans. New Haven: Yale University Press, 1952.
  • National Cancer Institute. Closing In on Cancer: Solving a 5,000-Year-Old Mystery (NIH publication 87-2955). Bethesda, Md: National Institutes of Health, 1987. Available at http://rex.nci.nih.gov/behindthenews/cioc/ciochome.htm.
  • Porter R. The Greatest Benefit to Mankind. New York: Norton, 1997: 574–580.
  • Cantor D. Cancer. In Bynum WF, Porter C, eds. Companion Encyclopedia of the History of Medicine, vol 1. London: Routledge, 1993: 537–561.
  • Cairns J. Matters of Life and Death: Perspectives on Public Health, Molecular Biology, Cancer, and the Prospects for the Human Race. Princeton: Princeton University Press, 1997.
  • Dobell C. Antony van Leeuwenhoek and His “Little Animals.” New York: Harcourt, Brace and Co, 1932.
  • Wintrobe MM. Blood, Pure and Eloquent. New York: McGraw-Hill, 1980.
  • Rather LJ. The Genesis of Cancer: A Study in the History of Ideas. Baltimore: Johns Hopkins University Press, 1978.
  • Parsonnett J, ed. Microbes and Malignancy: Infection as a Cause of Human Cancers. New York: Oxford, 1999.
  • Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357: 539–545.
  • Virchow R. Cellular Pathology as Based Upon Physiological and Pathological Histology. Chance F, trans. London: John Churchill, 1860.
  • Ackerknecht EH. Rudolf Virchow. Doctor, Statesman, Anthropologist. Madison: University of Wisconsin Press, 1953.
  • Varmus H, Weinberg RA. Genes and the Biology of Cancer. New York: Scientific American Library, 1993.
  • Gunz FW. Leukemia in the past. In Henderson ES, Lister TA, eds. Leukemia, 5th ed. Philadelphia: WB Saunders, 1990.
  • Freireich EJ, Lemak NA. Milestones in Leukemia Research and Therapy. Baltimore: Johns Hopkins University Press, 1991.
  • Kaplan HJ. Hodgkin's Disease, 2nd ed. Cambridge: Harvard University Press, 1980.
  • Aisenberg AC. Historical overview of malignant lymphoma. In Wiernik PH, Camellos GP, Dutcher JP, Kyle RA, eds. Neoplastic Diseases of the Blood, 3rd ed. New York: Churchill Livingstone, 1996:chap 36.
  • Kyle RA. History of multiple myeloma. In Wiernik PH, Camellos GP, Dutcher JP, Kyle RA, eds. Neoplastic Diseases of the Blood, 3rd ed. New York: Churchill Livingstone, 1996:chap 22.
  • Stone MJ. Henry Bence Jones and his protein. J Med Biogr 1998;6: 53–57.
  • Arnott H. Cancer, Its Varieties, Their Histologies and Diagnoses. London: JH Churchill, 1872.
  • Sutton JB. Tumours, Innocent and Malignant. Their Clinical Features and Appropriate Treatment. London: Cassel and Co Ltd, 1893.
  • Eisenberg RL. Radiology. An Illustrated History. St. Louis: Mosby, 1992.
  • Hayter CRR. The clinic as laboratory: the case of radiation therapy, 1896–1920. Bull Hist Med 1998;72: 663–688.
  • Kevles BH. Naked to the Bone. Medical Imaging in the Twentieth Century. Reading, Mass: Addison-Wesley, 1997.
  • Mullner R. Deadly Glow. The Radium Dial Worker Tragedy. Washington, DC: American Public Health Association, 1999.
  • Israel L. Conquering Cancer. New York: Random House, 1978.
  • Hall SS. A Commotion in the Blood. New York: Holt, 1997.
  • Cairns J. Cancer: Science and Society. San Francisco: WH Freeman, 1978.
  • Epstein SS. The Politics of Cancer Revisited. The Fremont Center, New York: East Ridge Press, 1998.
  • Rodu B, Cole P. The fifty-year decline of cancer in America. J Clin Oncol 2001;19: 239–241.
  • Gye WE, Purdy WJ. The Cause of Cancer. London: Cassell and Co Ltd, 1931.
  • Berenblum I. Man Against Cancer: The Story of Cancer Research. Baltimore: John Hopkins University Press, 1952.
  • Judson HF. The Eighth Day of Creation. New York: Simon and Schuster, 1979.
  • Currie GA. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer 1972;26: 141–153.
  • Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer, 2nd ed. Philadelphia: WB Saunders, 2001.
  • Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 1998.
  • Folkman J. Tumor angiogenesis. In Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine, 5th ed. Hamilton: BC Decker, 2000: 132–152.
  • Cooke R. Dr. Folkman's War. New York: Random House, 2001.
  • Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001;10: 677–685.
  • Stone MJ. Recent advances in oncology. Dallas Medical Journal 1978;64: 406–414.
  • Fidler IJ. Cancer biology: invasion and metastasis. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology, 2nd ed. New York: Churchill Livingstone, 2000: 29–53.
  • Cambrosio A, Keating P. Exquisite Specificity. The Monoclonal Antibody Revolution. New York: Oxford, 1995.
  • Stone MJ. Monoclonal antibodies in the prehybridoma era: a brief historical perspective and personal reminiscence. Clin Lymphoma 2001;2: 148–154.
  • Bainbridge WS. The Cancer Problem. New York: Macmillan, 1914.
  • Mann J. The Elusive Magic Bullet. The Search for the Perfect Drug. Oxford: Oxford University Press, 1999.
  • Gilman A, Phillips FS. The biological actions and therapeutic applications of b-chloroethyl amines and sulfides. Science 1946;103: 409–415.
  • Lazlo J. The Cure of Childhood Leukemia. Into the Age of Miracles. New Brunswick, NJ: Rutgers University Press, 1995.
  • Li MC, Hertz R, Spence DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956;93: 361.
  • Perry MC, Anderson CM, Donebower RC. Chemotherapy. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology, 2nd ed. New York: Churchill Livingstone, 2000: 378–422.
  • Savage DG, Antman KH. Imatinib mesylate—a new oral targeted therapy. N Engl J Med 2002;346: 683–693.
  • Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61: 6451–6458.
  • Demaitre L. Medieval notions of cancer: malignancy and metaphor. Bull Hist Med 1998;72: 609–637.
  • Sontag S. Illness as Metaphor. New York: Farrar, Straus and Giroux, 1977.
  • Patterson JT. The Dread Disease: Cancer in Modern American Culture. Cambridge: Harvard University Press, 1987.
  • Holland JC. Psycho-oncology. New York: Oxford University Press, 1998: 3–15.
  • Lerner BH. The illness and death of Eva Perón: cancer, politics, and secrecy. Lancet 2000;355: 1988–1991.
  • Lerner BH. The Breast Cancer Wars. New York: Oxford University Press, 2001.
  • Saunders CM. The Management of Terminal Disease. London: Edward Arnold, 1978.
  • Emanuel L. EPEC Trainer's Guide. Chicago: American Medical Association, 1999.
  • Hoxsey HM. You Don't Have to Die: The Amazing Story of the Hoxsey Treatment. New York: Milestone Books, 1956.
  • Cassileth BR. The Alternative Medicine Handbook. New York: Norton, 1998.
  • American Cancer Society's Guide to Complementary and Alternative Cancer Methods. Atlanta: American Cancer Society, 2000.
  • LaTour K. The Breast Cancer Companion. New York: William Morrow, 1993.
  • Harpham WS. Diagnosis: Cancer, Your Guide Through the First Few Months. New York: Norton, 1997.
  • Holland JC, Lewis S. The Human Side of Cancer. New York: Harper Collins (Quill), 2000.
  • 40th anniversary issue. J Ntl Cancer Inst 1977;59 (2 Supp).
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57–70.
  • Henderson L. Baylor University Medical Center: Yesterday, Today and Tomorrow. Waco: Baylor University Press, 1978: 240–246.
  • Baylor-Charles A. Sammons Cancer Center Annual Report 2000. Dallas: Baylor-Sammons Cancer Center.
  • Senzer NN. Docetaxel and radiation therapy for management of locally advanced prostate cancer. Advances in Prostate Cancer 2001;5 (3): 10–13.
  • Senzer NN. Prostate cancer: multimodality approaches with docetaxel. Semin Oncol 2001;28 (4 Suppl 15): 77–85.
  • Gordon AN, Hancock KC, Matthews CM, Stringer CA, Boston J, Nemunaitis J. A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. Am J Clin Oncol 1999;22: 601–605.
  • Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18: 3093–3100.
  • Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19: 3312–3322.
  • Baylor-Charles A. Sammons Cancer Center Annual Report 2001. Dallas: Baylor-Sammons Cancer Center.
  • Wistuba II, Tomlinson GE, Behrens C, Virmani A, Geradts J, Blum JL, Minna JD, Gazdar AF. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. Genes Chromosomes Cancer 2000;28: 359–369.
  • Blum JL, Jones SE, Fay JW, Senzer N, Mennel RG. Guidelines for systemic therapy of early stage breast cancer. Breast Cancer Res Treat 1997;43: 259–276.
  • Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17: 485–493; also Classic Papers and Current Comments: Breast Cancer 2001;5: 790–799.
  • O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12: 1247–1254.
  • O'Shaughnessy JA, Ljung BM, Dooley WC, Chang J, Kuerer HM, Hung DT, Grant MD, Khan SA, Phillips RF, Duvall K, Euhus DM, King BL, Anderson BO, Troyan SL, Kim J, Veronesi U, Cazzaniga M. Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer 2002;94: 292–298.
  • O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8: 314–346.
  • Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13: 2567–2574.
  • Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 1996;14: 2976–2983.
  • Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 1999;17: 3418–3425.
  • Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R, Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D, Rietz C. Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients. Clin Breast Cancer 2001;1: 310–314.
  • Jones SE, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, Blum J, Kirby R, Stone M, Pippen J, George T, Orr D, Knox S, Grant M, Peters G, Savino D, Rietz C. Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer. Clin Breast Cancer 2002;3: 147–152.
  • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371–1388.
  • Cheek JH, Sears AD. Results of breast biopsies for mammographic findings. Am J Surg 1978;136: 726–729.
  • Bailar JC III. Mammography: a contrary view. Ann Intern Med 1976;84: 77–84.
  • Mootz AR, Glazer-Waldman H, Evans WP, Peters GN, Kirk LM. Mammography in a mobile setting: remaining barriers. Radiology 1991;180: 161–165.
  • Peters GN, Vogel VG, Evans WP, Bondy M, Halabi S, Lord J, Laville EA. The Texas Breast Screening Project: Part I. Mammographic and clinical results. South Med J 1993;86: 385–390.
  • Evans WP, Cade SH. Needle localization and fine-needle aspiration biopsy of nonpalpable breast lesions with use of standard and stereotactic equipment. Radiology 1989;173: 53–56.
  • Cross MJ, Evans WP, Peters GN, Cheek JH, Jones RC, Krakos P. Stereotactic breast biopsy as an alternative to open excisional biopsy. Ann Surg Oncol 1995;2: 195–200.
  • Pierce WB, Harms SE, Flamig DP, Griffey RH, Evans WP, Hagans JE. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. Radiology 1991;181: 757–763.
  • Harms SE, Flamig DP, Evans WP, Harries SA, Brown S. MR imaging of the breast: current status and future potential. AJR Am J Roentgenol 1994;163: 1039–1047.
  • Soderstrom CE, Harms SE, Copit DS, Evans WP, Savino DA, Krakos PA, Farrell RS Jr, Flamig DP. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. Radiology 1996;201: 427–432.
  • Evans WP. Stereotactic breast biopsy. In Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia: JB Lippincott Co, 1996: 144–158.
  • Bassett L, Winchester DP, Caplan RB, Dershaw DD, Dowlatshahi K, Evans WP III, Fajardo LL, Fitzgibbons PL, Henson DE, Hutter RV, Morrow M, Paquelet JR, Singletary SE, Curry J, Wilcox-Buchalla P, Zinninger M. Stereotactic core-needle biopsy of the breast: a report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists. CA Cancer J Clin 1997;47: 171–190.
  • Brenner RJ, Bassett LW, Fajardo LL, Dershaw DD, Evans WP III, Hunt R, Lee C, Tocino I, Fisher P, McCombs M, Jackson VP, Feig SA, Mendelson EB, Margolin FR, Bird R, Sayre J. Stereotactic core-needle breast biopsy: a multi-institutional prospective trial. Radiology 2001;218: 866–872.
  • Evans WP III, Starr AL, Bennos ES. Comparison of the relative incidence of impalpable invasive breast carcinoma and ductal carcinoma in situ in cancers detected in patients older and younger than 50 years of age. Radiology 1997;204: 489–491.
  • Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, Fetzer JM, Herzig G, Bernstein GH. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84: 2151–2157.
  • Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996;87: 3514–3519.
  • Fay JW. Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer. Curr Opin Hematol 2002;9: 202–206.
  • Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15: 433–444.
  • US Oncology Annual Report 2000. Houston: US Oncology.
  • Research. In US Oncology Annual Report 2000. Houston: US Oncology.
  • Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6: 879–885.
  • Nemunaitis J, Eager R, Twaddell T, Corey A, Sekar K, Tkaczuk K, Thompson J, Hoff PM, Pazdur R. Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol 2000;18: 3423–3434.
  • Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000;60: 6359–6366.
  • Tong AW, Lee J, Stone MJ. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach. Cancer Res 1984;44: 4987–4992.
  • Tong AW, Lee JC, Stone MJ. Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells. Blood 1987;69: 238–245.
  • Tong AW, Zhang BQ, Mues G, Solano M, Hanson T, Stone MJ. Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 1994;84: 3026–3033.
  • Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7: 691–703.
  • Stone MJ, Klintmalm GB, Polter D, Husberg BS, Mennel RG, Ramsay MA, Flemens ER, Goldstein RM. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993;104: 196–202.
  • Stone MJ. Transplantation for primary hepatic malignancy. In Busuttil RW, Klintmalm GB, eds. Transplantation of the Liver. Philadelphia: WB Saunders, 1996: 120–129.
  • Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, Klintmalm GB, Stone MJ. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002;74: 1090–1095.
  • Collins RH Jr, Anastasi J, Terstappen LW, Nikaein A, Feng J, Fay JW, Klintmalm G, Stone MJ. Brief report: donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. N Engl J Med 1993;328: 762–765.
  • Collins RH Jr, Sackler M, Pitcher CJ, Waldrop SL, Klintmalm GB, Jenkins R, Picker LJ. Immune reconstitution with donor-derived memory/effector T cells after orthotopic liver transplantation. Exp Hematol 1997;25: 147–159.
  • Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr JW, Thorpe PE. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991;51: 4052–4058.
  • Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JWS, Vitetta ES. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82: 2624–2633.
  • Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996;88: 1188–1197.
  • Abrahm JL. A Physician's Guide to Pain and Symptom Management in Cancer Patients. Baltimore: Johns Hopkins University Press, 2000.
  • Stone MJ. Goals of care at the end of life. BUMC Proceedings 2001;14: 134–137.
  • Snyder L, Quill TE. Physician's Guide to End-of-Life Care. Philadelphia: American College of Physicians, 2001.
  • Stone MJ, Roberts WC. Marvin Jules Stone, MD, MACP: a conversation with the editor. BUMC Proceedings 2001;14: 422–438.
  • Weatherall D. Science and the Quiet Art: The Role of Medical Research in Health Care. New York: Norton, 1995.
  • Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002;20: 1932–1941.
  • Armstrong L, Jenkins S. It's Not About the Bike. New York: Putnam, 2000: 274.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.